The estimated Net Worth of Patrick D Walsh is at least $3.2 Milion dollars as of 21 March 2022. Mr. Walsh owns over 5,000 units of ANI Pharmaceuticals Inc stock worth over $2,900,036 and over the last 7 years he sold ANIP stock worth over $0. In addition, he makes $303,334 as Chairman of the Board at ANI Pharmaceuticals Inc.
Patrick has made over 6 trades of the ANI Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of ANIP stock worth $138,800 on 21 March 2022.
The largest trade he's ever made was buying 30,000 units of ANI Pharmaceuticals Inc stock on 23 March 2020 worth over $96,600. On average, Patrick trades about 2,783 units every 32 days since 2017. As of 21 March 2022 he still owns at least 53,388 units of ANI Pharmaceuticals Inc stock.
You can see the complete history of Mr. Walsh stock trades at the bottom of the page.
Patrick D. Walsh has been appointed as Chairman of the Board of the Company effective 9/8/2020. He is President & Managing Member of Diligence Team, LLC, a consulting practice he founded and is based in Durham, North Carolina. From 2015 to February 2019, Mr. Walsh was the chief executive officer of Avista Pharma, a private equity backed global provider of contract manufacturing, development and analytical testing services to pharmaceutical and biotechnology clients. Prior to Avista, from 2010 to 2014, Mr. Walsh was the chief executive officer of AAIPharma Services Corporation in Wilmington, North Carolina, a private equity backed global provider of contract manufacturing services. Mr. Walsh’s earlier career includes serving as chief executive officer of Kadmus Pharmaceuticals, Inc., in Irvine, California, and serving as president and chief operating officer of publicly-traded Gensia Sicor Pharmaceuticals, Inc. Mr. Walsh currently serves as an independent director of the Board of Directors of Avid Bioservices, a publicly-traded company based in Tustin, California and serves on its nominating committee. He is also an independent director of the Board of Directors of MedPharm LTD, a privately held company in Durham, North Carolina, and serves on its compensation committee. He is also an Operating Partner to healthcare private-equity firm Ampersand Capital, based in Wellesley, Massachusetts. Mr. Walsh is a member of the Board’s Audit and Finance and Compensation Committees. Mr. Walsh is nominated for re-election based on his 30-plus years of experience leading successful pharmaceutical manufacturing and development organizations and his significant prior experience as an independent director.
As the Chairman of the Board of ANI Pharmaceuticals Inc, the total compensation of Patrick Walsh at ANI Pharmaceuticals Inc is $303,334. There are 7 executives at ANI Pharmaceuticals Inc getting paid more, with Robert Schrepfer having the highest compensation of $2,160,980.
Patrick Walsh is 59, he's been the Chairman of the Board of ANI Pharmaceuticals Inc since 2020. There are 5 older and 9 younger executives at ANI Pharmaceuticals Inc. The oldest executive at ANI Pharmaceuticals Inc is Thomas Penn, 73, who is the Independent Director.
Patrick's mailing address filed with the SEC is C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE, MN, 56623.
Over the last 11 years, insiders at ANI Pharmaceuticals Inc have traded over $183,421,501 worth of ANI Pharmaceuticals Inc stock and bought 96,741 units worth $2,783,357 . The most active insiders traders include Arthur Przybyl, Venture Partners Ii Lp Meri... a Muthusamy Shanmugam. On average, ANI Pharmaceuticals Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,378,805. The most recent stock trade was executed by Meredith Cook on 13 August 2024, trading 250 units of ANIP stock currently worth $14,905.
ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.
ANI Pharmaceuticals Inc executives and other stock owners filed with the SEC include: